Fate Therapeutics (FATE) Interest Coverage Ratio (2012 - 2026)
Fate Therapeutics' (FATE) quarterly Interest Coverage Ratio came in at 0.28 in Q1 2026, up 10.9% YoY from 0.26 in Q1 2025, and up 64.85% on a QoQ basis from 0.81 in Q3 2025.
Fate Therapeutics (FATE) Interest Coverage Ratio (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 15 years of Interest Coverage Ratio data on file, last reported at 0.28 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 10.9% year-over-year to 0.28 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1.2 (up 22.49% YoY) and the FY2025 annual result came in at 0.38, up 34.45% from the prior year.
- Interest Coverage Ratio rose to 0.28 in Q1 2026, from 0.81 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 0.15 in Q4 2023 to a low of 4.65 in Q1 2022.
- A 5-year average of 0.93 and a median of 0.39 in 2023 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio surged 90.7% — and 2025, when it sank 1068.8%.
- Tracing FATE's Interest Coverage Ratio over 5 years: stood at 0.22 in 2022, then surged by 31.76% to 0.15 in 2023, then slipped by 14.92% to 0.17 in 2024, then plunged by 372.22% to 0.81 in 2025, then surged by 64.85% to 0.28 in 2026.
- The last three Interest Coverage Ratio figures came in at 0.28 (Q1 2026), 0.81 (Q3 2025), and 3.39 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | -0.28 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.28 |
| Sep 30, 2025 | -0.81 |
| Jun 30, 2025 | -3.39 |
| Mar 31, 2025 | -0.32 |
| Dec 31, 2024 | -0.17 |
| Sep 30, 2024 | -0.34 |
| Jun 30, 2024 | -0.29 |
| Mar 31, 2024 | -0.89 |
| Dec 31, 2023 | -0.15 |
| Sep 30, 2023 | -0.31 |
| Jun 30, 2023 | -0.98 |
| Mar 31, 2023 | -0.43 |
| Dec 31, 2022 | -0.22 |
| Sep 30, 2022 | -1.22 |
| Jun 30, 2022 | -0.45 |
| Mar 31, 2022 | -4.65 |
| Dec 31, 2021 | -0.31 |
| Sep 30, 2021 | -0.29 |
| Jun 30, 2021 | -0.58 |
| Mar 31, 2021 | -0.56 |